Cipla Completes 100% Acquisition of Inzpera Healthsciences

Indian multinational pharmaceutical company Cipla Ltd. has completed the acquisition of Inzpera Healthsciences Limited, integrating the healthsciences firm fully into its operations.

Cipla announced today, 4th December 2025, that it has successfully acquired a 100% stake in Inzpera.

This final step in the transaction means that Inzpera has officially become a wholly owned subsidiary of Cipla.

The completion of the acquisition follows Cipla’s prior intimation regarding the intended transaction, which was dated 3rd November 2025.

The move aligns Cipla, a major producer of pharmaceutical drugs and generic drugs, with Inzpera’s focus on the Healthsciences sector.

Inzpera’s core philosophy aims to address nutritional imbalances and poor health habits, thereby promoting wellness rather than focusing solely on illness.

The subsidiary plans to achieve this objective by introducing scientifically formulated everyday products and innovative solutions for healthier lives across various age groups.

Cipla, headquartered in Mumbai, notified the relevant stock exchanges, including the BSE Ltd., the National Stock Exchange of India Ltd., and SOCIETE DE LA BOURSE DE LUXEMBOURG, of the update.

Cipla’s equity shares are traded on the BSE (Scrip Code: 500087) and the NSE (Scrip Code: CIPLA EQ).

Rajendra Chopra, Company Secretary, signed the disclosure on behalf of Cipla Limited.

Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.

---